Panelists review the evolution of the cryogenic cold chain needs in this decade, with specific emphasis on what it takes to create a full ecosystem, taking into account the considerations all key stakeholders need and how we should be thinking about sustainable as well as integrated solutions.
During this discussion, our panel will examine the cell and gene therapy solutions that have been designed to overcome challenges in the cryogenic cold chain ecosystem. Looking ahead, we will consider what continued developments are needed to ensure end-to-end sustainability of this ecosystem.
By highlighting lessons learned from the COVID-19 pandemic, panelists will also emphasize the importance of both sustainable and automated cell and gene therapy processing to maintain a continuous supply chain and deliver critical treatments to clinic.
- Beth Webb, Commercial GM, Cell & Gene Therapy, Cytiva
- Dr. Stephen Ward, Chief Manufacturing Officer, Cell and Gene Therapy Catapult
- David Brochu, Chief Technical Officer, Autolus Therapeutics
- Alex Guite, Ph.D, Vice President, Services and Alliances, AmerisourceBergen World Courier & ICS